Ann: Race Leadership Changes, page-381

I can tell you JC has mentioned this figure in-person to more than one shareholder, and as recently as last year. Therefore, post-cardio discovery. This is deeply concerning to me and others, as he is the Chair.

If his stance has not changed, despite updated cardio/FTO market valuation(s), and this rationale (for $1bn ceiling) is not made clear to shareholders, I have to question the existing BOD's post and interests (ie, are the shareholder interests really reflected?).

If the BOD do not believe that Zantrene IP is worth in excess of $1bn, then we should demand to hear a clear rationale and the BOD should address this.

The ball is in the BOD's court to address valuation - and do so in a timely manner if threat of lowballing is real (and it is, we all need to understand that).

Please consider the actions last week as a canary in the mine.

All IMO.